Home / Tag Archives: CKD

Tag Archives: CKD

Can AI and Digital Pathology Detect Diabetic Kidney Disease Earlier?

Artificial intelligence analyzing a digital kidney biopsy slide for early detection and classification of diabetic kidney disease in a pathology laboratory.

Artificial intelligence is rapidly changing how healthcare professionals diagnose disease. But can computers identify kidney damage before it becomes obvious under a microscope? Researchers believe the answer may be yes. The combination of digital pathology, artificial intelligence, and diabetic kidney disease research is opening new opportunities to identify microscopic kidney …

Read More »

Not All Diabetic Kidney Disease Is the Same—Scientists Just Found a Hidden Subtype

Medical illustration showing a human kidney with an enlarged view of immune B-cell activity, representing a newly discovered diabetic kidney disease subtype associated with kidney inflammation.

For years, diabetic kidney disease (DKD) has been viewed as a single condition that progresses in a fairly predictable way. However, new research suggests that this assumption may overlook important biological differences between patients. Scientists have now identified a previously hidden subtype of diabetic kidney disease marked by increased B-cell …

Read More »

Farxiga Just Went Generic—Will Lower Prices Finally Change Diabetes Care?

Prescription bottle of generic dapagliflozin (Farxiga) beside a blood glucose meter, stethoscope, heart model, and kidney model representing diabetes, cardiovascular, and kidney care.

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …

Read More »

Beyond SGLT2 Inhibitors: Why Non-Steroidal MRAs Are Becoming the Third Pillar of Kidney Protection

Illustration of healthy kidneys with medication representing non-steroidal mineralocorticoid receptor antagonists alongside SGLT2 inhibitor therapy for diabetic kidney disease management.

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …

Read More »